Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant

View ORCID ProfileWan Yang, View ORCID ProfileSharon K. Greene, Eric R. Peterson, Wenhui Li, Robert Mathes, Laura Graf, Ramona Lall, Scott Hughes, Jade Wang, Anne Fine
doi: https://doi.org/10.1101/2021.08.04.21261596
Wan Yang
1Department of Epidemiology, Mailman School of Public Health, Columbia University
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wan Yang
  • For correspondence: wy2202@cumc.columbia.edu
Sharon K. Greene
2Bureau of Communicable Disease, New York City Department of Health and Mental Hygiene
PhD, MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sharon K. Greene
Eric R. Peterson
2Bureau of Communicable Disease, New York City Department of Health and Mental Hygiene
MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenhui Li
3Bureau of Vital Statistics, New York City Department of Health and Mental Hygiene
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Mathes
2Bureau of Communicable Disease, New York City Department of Health and Mental Hygiene
MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Graf
2Bureau of Communicable Disease, New York City Department of Health and Mental Hygiene
MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ramona Lall
2Bureau of Communicable Disease, New York City Department of Health and Mental Hygiene
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Hughes
4Public Health Laboratory, New York City Department of Health and Mental Hygiene
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jade Wang
4Public Health Laboratory, New York City Department of Health and Mental Hygiene
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Fine
2Bureau of Communicable Disease, New York City Department of Health and Mental Hygiene
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The B.1.526 variant (WHO designation: Iota) is a SARS-CoV-2 variant of interest, as classified by both the US CDC and the WHO. Due to a lack of extensive genomic sequencing and contact tracing data, its key epidemiological properties have not been well characterized.

Methods We utilized nine epidemiological and population datasets collected in New York City (NYC), where B.1.526 emerged, and comprehensive modeling to estimate the changes in transmissibility, immune escape potential, and infection fatality risk (IFR) for B.1.526.

Findings Estimated transmission rate in the neighborhood where B.1.526 was initially detected was consistently higher than other neighborhoods in NYC and further increased during the weeks preceding B.1.526 detection, likely due to its early spread there. Overall, models estimated that B.1.526 had transmissibility about 15-25% higher than previously circulating variants and that it could escape immunity in 0-10% of previously infected persons. In addition, B.1.526 substantially increased IFR in older adults: by 46% (95% CI: 7.4 – 84%) among 45-64 year-olds, 82% (95% CI: 20 – 140%) among 65-74 year-olds, and 62% (95% CI: 45 – 80%) among 75+ during Nov 2020 – Apr 2021, compared to baseline IFR estimated for preexisting variants.

Interpretation New variants like B.1.526 likely spread in the population weeks prior to detection, and partial immune escape (e.g., resistance to therapeutic antibodies) could offset prior medical advances and increase IFR. Early preparedness for and close monitoring of SARS-CoV-2 variants, their epidemiological characteristics, and disease severity are thus crucial to COVID-19 pandemic response as it remains a global public health threat.

Evidence before this study We searched PubMed for studies published through June 23, 2021 on the B.1.526 (Iota) SARS-CoV-2 variant, using the terms “B.1.526”, “Iota variant” and “COVID-19”, or “Iota variant” and “SARS-CoV-2”. Our search returned 14 papers, from which we read the abstracts and identified 8 relevant studies. The majority (7 of 8) of these studies focused on identifying the specific mutations, namely L5F, T95I, D253G, additionally E484K or S477N for two different subclades (i.e., B.1.526-S:E484K and B.1.526-S:S477N) and a closely related subclade (i.e., B.1.526-S:L452R or B.1.526.1) as defined by spike mutations D80G, Δ144, F157S, L452R, T859N, and D950H; these studies also examined changes in neutralizing ability of convalescent plasma and vaccinee sera (mild reductions by ∼2-4 fold were reported) and changes in neutralizing ability of monoclonal antibodies (substantial reductions for some monoclonal antibodies were reported). Two studies used genomic data from GISAID to estimate the growth rate of B.1.526 during January - March 2021 and reported that it was similar to the Alpha variant (i.e., B.1.1.7), a SARS-CoV-2 variant of concern with around 50% higher transmissibility than preexisting variants. However, an epidemiological study using individual patient data from January 1 to April 5, 2021 reported no increases in secondary attack rate among contacts of B.1.526 cases, compared to non-VOC/VOI variants. This latter study also showed preliminary evidence that B.1.526 did not increase the risk of hospitalization or death, nor of vaccine breakthrough or reinfection.

Added value of this study We utilized multiple datasets collected in New York City – where B.1.526 emerged – and model-inference methods to reconstruct the transmission dynamics, including the initial emergence of B.1.526 in the fall of 2020. We estimated that B.1.526 had a moderate increase (15-25%) in transmissibility and could escape immunity in 0-10% of previously infected individuals. In addition, B.1.526 substantially increased the infection-fatality risk (IFR) among adults 65 or older by >60% during Nov 2020 – Apr 2021, compared to baseline risk estimated for preexisting variants.

Implications of all the available evidence New SARS-CoV-2 variants like B.1.526 could increase transmissibility, evade prior immunity, and increase disease severity. Early preparedness for and close monitoring of SARS-CoV-2 variants and their epidemiological characteristics are crucial to COVID-19 pandemic response as it remains a global public health threat.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by the National Institute of Allergy and Infectious Diseases (AI145883) and the NYC DOHMH.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was classified as public health surveillance and exempt from ethical review and informed consent by the Institutional Review Boards of both Columbia University and NYC DOHMH.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The COVID-19 case and mortality data were used with permission under a Data Use and Nondisclosure Agreement between the New York City Department of Health and Mental Hygiene (DOHMH) and Columbia University. The NYC DOHMH also has a comprehensive, publicly available data website here: https://github.com/nychealth/coronavirus-data. Additional data sources are detailed in the manuscript.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted August 07, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant
Wan Yang, Sharon K. Greene, Eric R. Peterson, Wenhui Li, Robert Mathes, Laura Graf, Ramona Lall, Scott Hughes, Jade Wang, Anne Fine
medRxiv 2021.08.04.21261596; doi: https://doi.org/10.1101/2021.08.04.21261596
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant
Wan Yang, Sharon K. Greene, Eric R. Peterson, Wenhui Li, Robert Mathes, Laura Graf, Ramona Lall, Scott Hughes, Jade Wang, Anne Fine
medRxiv 2021.08.04.21261596; doi: https://doi.org/10.1101/2021.08.04.21261596

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (577)
  • Anesthesia (139)
  • Cardiovascular Medicine (1942)
  • Dentistry and Oral Medicine (252)
  • Dermatology (183)
  • Emergency Medicine (331)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (697)
  • Epidemiology (11088)
  • Forensic Medicine (8)
  • Gastroenterology (620)
  • Genetic and Genomic Medicine (3159)
  • Geriatric Medicine (307)
  • Health Economics (561)
  • Health Informatics (2040)
  • Health Policy (862)
  • Health Systems and Quality Improvement (782)
  • Hematology (309)
  • HIV/AIDS (682)
  • Infectious Diseases (except HIV/AIDS) (12702)
  • Intensive Care and Critical Care Medicine (707)
  • Medical Education (317)
  • Medical Ethics (92)
  • Nephrology (334)
  • Neurology (2979)
  • Nursing (163)
  • Nutrition (462)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1548)
  • Ophthalmology (475)
  • Orthopedics (185)
  • Otolaryngology (265)
  • Pain Medicine (201)
  • Palliative Medicine (57)
  • Pathology (402)
  • Pediatrics (910)
  • Pharmacology and Therapeutics (381)
  • Primary Care Research (354)
  • Psychiatry and Clinical Psychology (2775)
  • Public and Global Health (5584)
  • Radiology and Imaging (1090)
  • Rehabilitation Medicine and Physical Therapy (631)
  • Respiratory Medicine (756)
  • Rheumatology (338)
  • Sexual and Reproductive Health (311)
  • Sports Medicine (287)
  • Surgery (342)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (131)